News
So, Should We Worry About Recursion Pharmaceuticals' Cash Burn? As you can probably tell by now, we're not too worried about Recursion Pharmaceuticals' cash burn.
Recursion's AI-designed cancer drugs REC-3565 and REC-617 show early clinical promise, with one patient responding unexpectedly well to treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback